Going beyond Cancer with T cell engagers: First-in-human report on a CD19 TCE for safe & successful treatment in systemic sclerosis. EJC in press. Oncology Advance

How does the gut microbiome affect the efficacy of CAR T-cell therapy in patients with hematological malignancies? Prof. MariSubklewe discusses in our podcast.

Full episode available below!

👉 bit.ly/42S9xy1 👈

#OncTwitter #BloodCancer #HaemOnc

#ESHAL2024 Many thanks to Dombret Hervé @Gossenkoppele Christoph Röllig Wendy Stock for putting together such an exciting program to all faculty for a great meeting & to all participants for the lively interaction!
See you next year for #ESHALL2025 & #ESHAML2025
#ESHCONFERENCES

Check out our European Hematology Association The EBMT consensus guidelines for a new distinct toxicity category of immune effector cell therapy (CAR-T, BsAb): ICAHT!

See link above for the accompanying commentary !

Also featured in the Blood Journal podcast 👇
ashpublications.org/blood/pages/bl…

Great to see our European Hematology Association and The EBMT consensus guidelines article on immune effector cell-associated hematotoxicity out in full print in Blood Journal ! 🎉🎉🎉

Very proud of this European team effort!

ashpublications.org/blood/article/…

Professorinnen @LMU – gemeinsam für die neue Ära der Spitzenmedizin. Female professors LMU Klinikum München - together for the new era of cutting-edge medicine. Universität München; #WomenInMedicine ; #WomenInSTEM #female scientists ; #academia ; #female ; #equality #Diversity

Kai Rejeski MariSubklewe you made it to the icml highlights👍

Kudos to the #EHA #EBMT team on putting together #ICAHT consensus guidelines now published in Blood Journal. Grateful for this incredible European collaboration and a special shoutout to Kai Rejeski

Real honor to present our consensus grading and best practice recommendations for immune effector cell-associated hematotoxicity (ICAHT) on behalf of European Hematology Association and The EBMT and entire team today at #EHA23 !

Manuscript out in parallel Blood Journal

ashpublications.org/blood/article/…

Brilliant Habilitation Presentation by Kai Rejeski last nite at the LMU medical faculty colloquium. Congrats to this impressive publication track record - honored to be one of his mentors.

RWE of EU & US practice patterns of Immune Effector Cell Associated Hematotoxicity (ICAHT) post #CAR T . Fantastic collaborative work with @EBMT @EHA and international #CAR community. Check out our survey journals.lww.com/hemasphere/Ful…. Kai Rejeski Ibrahim Yakoub-Agha @ annasureda5

Filled with great joy & gratitude for an inspiring networking event of #FAME , a newly founded network of female university professors at the LMU Medical Faculty that fosters female careers and prepares the next generation of female leaders in academic medicine. Many more to come.

Great to participate in this study aiming to identify infection vs CRS after #CART therapy, always a pleasure with Kai Rejeski MariSubklewe

#ISAL2023 | MariSubklewe of Universität München shares some insights into the current status of bispecifics in AML and challenges to overcome.

Watch here:

👉ow.ly/2Klo50Nr3EF👈

#AMLsm #LeuSM #ImmunoOnc #HemOnc

Next month, we'll be heading to #ISAL2023 to speak with experts who will bring you the latest in acute leukemias!

Find out more below:

👉ow.ly/LMNT50MWQzz👈

#ISALXVIII #AMLsm #ALLsm #LeuSM #HemOnc MariSubklewe International Symposium Acute Leukemias - Munich

MariSubklewe CAR-HEMATOTOX score! #CART23

Very interesting and helpful tool in complications clinical management

Infectious Diseases in #CARTcells is an important scenario we have to deal with!

The EBMT European Hematology Association The EBMT_Trainee YoungEHA

Excellent presentation by Veit Bücklein on EU vs US clinical outcomes for 3L CD19 targeted CAR-T in LBCL. It was great to work on this project Kai Rejeski MariSubklewe Michael Jain

Dr ⁦MariSubklewe⁩ for ⁦IACH⁩ News. Thank you for such an in depth analysis of T cell exhaustion when using bispecific antibodies. Superb arricle in ⁦Blood Journal⁩ ⁦ASH⁩ ⁦⁦@MyelomaTeacher - Cindy Chmielewski⁩ ⁦Jim Omel on.soundcloud.com/k4EtJ

📣 Veranstaltungshinweis 📣
#Nebenwirkungen der CAR-T-Zell Therapie sind das Thema des heutigen Online-Seminars der #CancerSchool .
MariSubklewe vom LMU Klinikum München wird von 🕠 17:30 bis 18 Uhr Fragen dazu beantworten. Mehr Infos unter 👉 cancerschool.de/nebenwirkungen…
#XgegenKrebs

Looking forward to moderating patient questions on CAR T-cell toxicity after a talk by Prof. Marion Subklewe MariSubklewe LMU Klinikum München on Nov 10: bit.ly/3fD9Nx3 Do join us virtually for free! Great patient-centered lecture series, funded by Deutsche Krebshilfe Krebsgesellschaft